Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Other Accumulated Expenses: 2011-2023

Historic Other Accumulated Expenses for Lineage Cell Therapeutics (LCTX) over the last 11 years, with Jun 2023 value amounting to $1,000.

  • Lineage Cell Therapeutics' Other Accumulated Expenses fell 90.00% to $1,000 in Q2 2023 from the same period last year, while for Jun 2023 it was $1,000, marking a year-over-year decrease of 90.00%. This contributed to the annual value of $178,000 for FY2021, which is 1877.78% up from last year.
  • Lineage Cell Therapeutics' Other Accumulated Expenses amounted to $1,000 in Q2 2023, which was down 97.30% from $37,000 recorded in Q1 2023.
  • In the past 5 years, Lineage Cell Therapeutics' Other Accumulated Expenses ranged from a high of $492,000 in Q2 2021 and a low of $1,000 during Q2 2023.
  • In the last 3 years, Lineage Cell Therapeutics' Other Accumulated Expenses had a median value of $69,000 in 2021 and averaged $118,778.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Other Accumulated Expenses soared by 1,877.78% in 2021 and then slumped by 97.97% in 2022.
  • Over the past 5 years, Lineage Cell Therapeutics' Other Accumulated Expenses (Quarterly) stood at $4,000 in 2019, then spiked by 125.00% to $9,000 in 2020, then skyrocketed by 1,877.78% to $178,000 in 2021, then plummeted by 63.77% to $25,000 in 2022, then crashed by 90.00% to $1,000 in 2023.
  • Its Other Accumulated Expenses was $1,000 in Q2 2023, compared to $37,000 in Q1 2023 and $25,000 in Q3 2022.